arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Alpha Teknova, Inc.

TKNO
$8.74 ▲ +0.38 (+4.55%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
7 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Alpha Teknova, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $467.4M
Dividend Yield
Revenue Growth 7.4%
Op. Margin -41.9%
ROIC -20.8%
FCF / Share $-0.18
Trailing P/E
Price / Book 6.8x
FCF Yield
Debt / Equity 0.19
info Valuation on last close. End-of-day price, Sep 22, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$40.52M
↑ +7.4%
Net Income Profit after all expenses
$-17.26M
↑ +35.5%
Operating Margin Operating profit as % of sales
-41.9%
↑ +39.5% 6th
FCF / Share Free cash flow per share
$-0.18
↑ +36.7%
Long-Term Debt Long-term obligations
$13.12M
↑ +39.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
7
Returns
25
Financial Health
51
Cash Quality
43

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters